Rani Therapeutics has developed a novel approach for the oral delivery of large drug molecules including peptides, proteins and antibodies. We are currently in pre-clinical studies and have demonstrated greater than 50% bioavailability. View a snapshot of our results with Adalimumab and human insulin.
We are currently exploring partnerships with pharmaceutical companies. Contact us to learn more about our innovation and approach.
